Skip to main content
HWAIL PHARM. CO., LTD logo

HWAIL PHARM. CO., LTD — Investor Relations & Filings

Ticker · 061250 ISIN · KR7061250007 KO Manufacturing
Open in API
Filings indexed 273 across all filing types
Latest filing 2026-03-24 Declaration of Voting R…
Country KR South Korea
Listing KO 061250

About HWAIL PHARM. CO., LTD

http://www.hwail.com/

Hwail Pharm. Co., Ltd. is a pharmaceutical company that specializes in the research, development, manufacturing, and distribution of Active Pharmaceutical Ingredients (APIs). The company also provides a range of finished drug formulations, including generic and patented medications, as well as functional health products. A core focus of the organization is maintaining high standards through continuous R&D investment and rigorous quality control processes to develop and produce its pharmaceutical products.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is titled “정기주주총회결과” (Regular Shareholders’ Meeting Results) and provides detailed voting outcomes for each agenda item, including approval of financial statements, share consolidation, amendments to the articles of incorporation, director appointments, and remuneration limits. It clearly reports the official vote results from an AGM. This matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-03-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 90% confidence The document is a Korean insider shareholding report (“임원ㆍ주요주주 특정증권등 소유상황보고서”) detailing an executive’s securities ownership changes, including number of shares, dates of transactions, acquisition/disposal prices, and ownership ratios. This matches the definition of “Director’s Dealing” for personal share transactions by company directors. Therefore, the appropriate classification is DIRS.
2026-03-23 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 45th fiscal year (2025) of Hwail Pharmaceutical Co., Ltd. It contains detailed corporate information, history, capital changes, shareholding structure, and governance details. In the Korean regulatory context, the 'Business Report' (사업보고서) is the equivalent of the annual comprehensive filing submitted to the Financial Supervisory Service (FSS), which corresponds to the 10-K filing type in the provided schema. FY 2025
2026-03-16 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion, key financial data, and auditor information for the fiscal year ending 2025-12-31. While it contains financial data, it is a standalone regulatory disclosure of the audit results rather than a full Annual Report (10-K) or a simple announcement of report publication (RPA). Therefore, it falls under the 'Audit Report / Information' category. FY 2025
2026-03-12 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for Hwail Pharmaceutical. It details the date, location, agenda items (such as financial statement approval, director appointments, and articles of incorporation changes), and voting record dates. This is a standard proxy solicitation document used to inform shareholders of an upcoming meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2026-03-09 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Hwail Pharmaceutical Co., Ltd. It contains the agenda for the upcoming Annual General Meeting (AGM), including financial statement approval, board appointments, and governance matters. It also includes management's business report and financial statements (balance sheet, income statement, etc.) as reference materials for shareholders. According to the filing definitions, materials shared for an AGM are classified as AGM-R.
2026-03-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.